

**Omadacycline (PTK 0796) Publications/Posters/Oral Presentations**

<b>Publications</b>				
<b>Date</b>	<b>Journal</b>	<b>Citation</b>	<b>First Author</b>	<b>Title</b>
May, 2017	Antimicrob. Agents and Chemother.	61:e02434-16	Steenbergen	<b>In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis</b>
May, 2017	Antimicrob. Agents and Chemother.	61:e02368-16	Lepak	<b>In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model</b>
May, 2017	Antimicrob. Agents and Chemother.	61:e00018-17	Pfaller	<b>Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011</b>
March, 2017	Antimicrob. Agents and Chemother.	61: e02411-16	Pfaller	<b>Activity of Omadacycline and Comparator Agents When Tested against Staphylococcus aureus from a Surveillance Program Conducted in North America and Europe</b>
March, 2017	J. Clin. Pharmacol.	57(3): 321-327	Tzanis	<b>Effect of Food on the Bioavailability of Omadacycline in Healthy Subjects</b>
Jan, 2017	Antimicrob. Agents and Chemother.	61: e01784-16	Lin	<b>Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline Following a Single Intravenous or Oral Dose of <sup>14</sup>C-omadacycline in Rats</b>
Dec, 2016	Bioorg. Med. Chem.	24(2016): 6409-6419	Tanaka	<b>Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic</b>
Dec, 2016	Antimicrob. Agents and Chemother.	60(12): 7431-7435	Sun	<b>A Randomized, Open-label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects</b>
Dec, 2016	Antimicrob. Agents and Chemother.	60(12): 7502-7504	Waites	<b>In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas</b>
Oct, 2016	Future Microbiol.	11(11): 1421-1434	Villano	<b>Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections</b>
Sept, 2016	Antibiotics	5: 32	Heidrich	<b>The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome</b>

Sept, 2016	Antimicrob. Agents and Chemother.	60(9): 5247-5253	Tanaka	<b>In Vitro and In Vivo Assessment of Cardiovascular Effects with Omadacycline</b>
Aug, 2016	Xenobiotica	Accepted, epub ahead of print	Flarakos	<b>Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline</b>
Nov, 2015	Antimicrob. Agents and Chemother.	59(11): 7044-7053	Honeyman	<b>Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline</b>
March, 2014	Antimicrob. Agents and Chemother.	58(3): 1279–1283	Draper	<b>Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline</b>
Feb, 2014	Antimicrob. Agents and Chemother.	58(2): 1127-1135	Macone	<b>In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline</b>
Nov, 2012	Antimicrob. Agents and Chemother.	56(11): 5650-5654	Noel	<b>A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections</b>

<b>Posters and Oral Presentations</b>				
<b>Date</b>	<b>Conference</b>	<b>Presentation number</b>	<b>First Author</b>	<b>Title</b>
Apr 22-25, 2017	ECCMID	OS0606	O’Riordan (presented by Loh)	<b>A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study)</b>
Apr 22-25, 2017	ECCMID	P1252	O’Riordan	<b>Efficacy of Oral and IV Omadacycline vs. Linezolid for Treating Adult Subjects With ABSSSI: Analysis by Infection Type and Pathogen in the OASIS Study</b>
Apr 22-25, 2017	ECCMID	P1253	Huband	<b>In vitro activity of omadacycline and comparators against Gram-negative bacterial isolates collected from patients in European medical centres (2016): results from the SENTRY antimicrobial surveillance programme</b>
Apr 22-25, 2017	ECCMID	P1254	Dubois	<b>In vitro extracellular and intracellular activity of omadacycline against Staphylococcus aureus</b>
Apr 22-25, 2017	ECCMID	P1255	O’Riordan	<b>Efficacy of omadacycline versus linezolid in treating ABSSSI patients from different geographic regions (OASIS trial)</b>

Apr 22-25, 2017	ECCMID	P1256	Overcash	<b>Effects of IV/oral omadacycline versus IV/oral linezolid on lesion size and local signs of ABSSSI in the phase 3 OASIS trial</b>
Apr 22-25, 2017	ECCMID	P1257	Gotfried	<b>Safety and Tolerability of IV Omadacycline (OMC) and Tigecycline (TGC) in Healthy Subjects in a Study to Assess Intra-Pulmonary Steady-State Concentrations</b>
Apr 22-25, 2017	ECCMID	P1262	Huband	<b>In vitro activity of omadacycline and comparators against staphylococci, streptococci and enterococci (including resistant organism subsets) from patients in European medical centres during 2016: results from the SENTRY antimicrobial surveillance programme</b>
Apr 22-25, 2017	ECCMID	P1263	Thwaites	<b>The impact of non-standard test conditions on the in-vitro activity of omadacycline by broth microdilution</b>
Apr 22-25, 2017	ECCMID	P1264	Stapert	<b>The in-vitro activity of omadacycline and comparators against anaerobic bacteria</b>
Apr 22-25, 2017	ECCMID	P1265	LaPensee	<b>Economic impact of omadacycline among acute bacterial skin and skin structure infections (ABSSSIs) patients: cost-saving opportunities due to avoidable hospitalizations using an antibiotic with IV-to-oral switch capability</b>
Apr 22-25, 2017	ECCMID	P1266	LaPensee	<b>Cost-saving opportunities among hospitalized patients with acute bacterial skin and skin structure infections with omadacycline, a once-daily antibiotic with IV-to-oral transition capability, relative to current standard of inpatient care</b>
Apr 22-25, 2017	ECCMID	OS1018	Horn	<b>Comparison of Omadacycline (OMC) and Tigecycline (TGC) Pharmacodynamics (PD) in the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Subjects</b>
Oct 26-30, 2016	IDWEEK	1827	Flamm	<b>Activity of Omadacycline When Tested Against Gram-positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program</b>
June 16-20, 2016	ASM Microbe	MONDAY-001	Sweeney	<b>Activity of Omadacycline Against Clinical Isolates of Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Isolates</b>
June 16-20, 2016	ASM Microbe	MONDAY-509	Van Wart	<b>Population Pharmacokinetics (PPK) of Omadacycline (OMC) Following Intravenous (IV) or Oral Administration and Evaluation of Phase 3 Sparse PK Sampling Strategies</b>
June 16-20, 2016	ASM Microbe	MONDAY-510	Van Scoy	<b>Evaluation of the In Vitro Activity Profile of Omadacycline Against Haemophilus influenzae</b>

June 16-20, 2016	ASM Microbe	MONDAY-512	Hinshaw	<b>Post-antibiotic Effect of Omadacycline Against Target Pathogens</b>
June 16-20, 2016	ASM Microbe	MONDAY-518	Villano	<b>In Vitro Protein Binding with Omadacycline, a First in Class Aminomethylcycline Antibiotic</b>
June 16-20, 2016	ASM Microbe	MONDAY-519	Tzanis	<b>Effect of Food on the Bioavailability of Omadacycline in Healthy Volunteers</b>
June 16-20, 2016	ASM Microbe	MONDAY-551	Dubois	<b>In Vitro Intracellular Activity of Omadacycline against Legionella pneumophila</b>
June 16-20, 2016	ASM Microbe	MONDAY-552	Diehl	<b>In Vitro Activity of Omadacycline Against Escherichia coli Biofilms</b>
June 16-20, 2016	ASM Microbe	MONDAY-567	Tracjewski	<b>Omadacycline (PTK0796) Spectrum of Activity from 2003 through 2015</b>
April 9-12, 2016	ECCMID	P1324	Chilton	<b>Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of the human gut</b>
April 9-12, 2016	ECCMID	P1323	Dubois	<b>In Vitro Bacterial and Intracellular Activity of Omadacycline against Legionella pneumophila</b>
April 9-12, 2016	ECCMID	P1317	Flamm	<b>Omadacycline activity tested against European bacterial isolates from a combined 2010-2011 Global Surveillance program</b>
April 9-12, 2016	ECCMID	P1322	Hawser	<b>Bactericidal activity of omadacycline, a novel aminomethylcycline</b>
April 9-12, 2016	ECCMID	P1325	Kim	<b>Activity and Efficacy of Omadacycline against Clostridium difficile</b>
April 9-12, 2016	ECCMID	P1318	Tanaka	<b>Effect of Age and Gender on the Pharmacokinetics of the Oral and IV Omadacycline, A New Class of Aminomethylcyclines</b>
April 9-12, 2016	ECCMID	P1326	Tanaka	<b>A Pooled Analysis of Two Randomized Multicenter, Evaluator-Blind Studies Comparing the Safety and Efficacy of Omadacycline and Linezolid for the Treatment of Complicated Skin and Skin Structure Infections</b>
April 9-12, 2016	ECCMID	P1319	Tanaka	<b>Single and Multiple Dose Pharmacokinetics and Tolerability of Intravenous Omadacycline in Healthy Volunteers</b>
April 9-12, 2016	ECCMID	P1320	Van Wart	<b>Population Pharmacokinetics (PPK) of Omadacycline Following Intravenous or Oral Administration to Phase 1 Subjects</b>
April 9-12, 2016	ECCMID	P1321	Villano	<b>Omadacycline, an Aminomethylcycline Antibiotic, Has No Effect on QT/QTc Intervals in Healthy Subjects</b>

Sept 17-21, 2015	ICAAC	C-554	Flamm	<b>Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	C-614	Flamm	<b>Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	F-289	Flamm	<b>Activity of Omadacycline Tested against Staphylococcus aureus from a Global Surveillance Program (2014)</b>
Sept 17-21, 2015	ICAAC	D-194	Traczewski	<b>Quality Control Parameters for Broth Microdilution and Agar dilution Susceptibility Tests of Omadacycline (formerly PTK-0796) against B. fragilis ATCC 25285, B. thetaiotaomicron ATCC 29741, E. lenta ATCC 43055, and C. difficile ATCC 700057 Using Fresh Media</b>
Sept 17-21, 2015	ICAAC	D-195	Traczewski	<b>Omadacycline (formerly PTK-0796) In Vitro Spectrum of Activity and Confirmation of Disk Mass Using Fresh Media for MIC Testing</b>
Sept 17-21, 2015	ICAAC	D-1140	Traczewski	<b>Quality Control Parameters for Omadacycline Minimum Inhibitory Concentration (MIC) Susceptibility Tests.</b>
Sept 17-21, 2015	ICAAC	F-770	DuBois	<b>In Vitro Activity of Omadacycline Against Legionella pneumophila</b>
Feb 25-27, 2013	ASM Biodefense	253(G)	Draper	<b>In Vitro Activity of Omadacycline (OMC) against Biothreat Bacteria</b>
Sept 9-12, 2012	ICAAC	A-1282	Ting	<b>Pharmacokinetics of Omadacycline (PTK0796) in Subjects with Hepatic Impairment</b>
Sept 9-12, 2012	ICAAC	A-1281	Sun	<b>Pharmacokinetics of [14C]-labeled Omadacycline (PTK 0796) in Healthy Male Subjects</b>
Mar 31- Apr 3, 2012	ECCMID	P694	Noel	<b>Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI)</b>
Mar 31- Apr 3, 2012	ECCMID	P1422	Hanna	<b>Metabolic Stability of PTK 0796 (Omadacycline)</b>
Mar 31- Apr 3, 2012	ECCMID	P1423	Sun	<b>A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects</b>
Mar 31- Apr 3, 2012	ECCMID	P1424	Hanna	<b>Lack of Interaction of PTK 0796 (Omadacycline) with Human Transporter</b>
Mar 31- Apr 3, 2012	ECCMID	P1449	Flamm	<b>Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union</b>

Mar 31- Apr 3, 2012	ECCMID	P1450	Sader	<b>Antimicrobial Activity of PTK 0796 (Omadacycline) Tested against Gram-positive Organisms Isolated from European Hospitals in 2011</b>
Sept 17-20, 2011	ICAAC	C1-609	Ruzin	<b>Omadacycline (PTK796) Mechanism of Action Studies by Using In Vitro Protein Synthesis Inhibition Assay and Molecular Modeling</b>
May 7-10, 2011	ECCMID	P1528	Hait	<b>In a Phase 2 Complicated Skin and Soft Tissue Infections Trial, Outcomes Assessed Early in the Course of Therapy were Consistent with Outcomes 10-17 Days After Completing Therapy with Either Omadacycline (OMC; PTK796) or Linezolid</b>
May 7-10, 2011	ECCMID	P1074	Leahy	<b>Comparative Efficacy of Omadacycline (PTK796) in Lethal Streptococcus pneumoniae and Staphylococcus aureus Pneumonia Models</b>
May 7-10, 2011	ECCMID	P1141	Macone	<b>In vitro Activity of Omadacycline (PTK796) in Broth Plus Lung Surfactant or Human Serum</b>
Sept 12-15, 2010	ICAAC	B-069	Yu	<b>Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model</b>
Sept 12-15, 2010	ICAAC	C1-1413	Ruzin	<b>Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumonia</b>
Sept 12-15, 2010	ICAAC	E-1569	Biedenbach	<b>In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe</b>
Sept 12-15, 2010	ICAAC	E-1588	Sader	<b>Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009</b>
Sept 12-15, 2010	ICAAC	K-124	Ting	<b>Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic</b>
Sept 12-15, 2010	ICAAC	L1-1760	Macone	<b>Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK0796 (PTK) Phase 2 Clinical Trial</b>
Oct 25-28, 2008	ICAAC	L-1515b	Arbeit	<b>Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step Down Therapy</b>
Sept 27-30, 2006	ICAAC	F1-1971	Smith	<b>Antistaphylococcal Activity of MK-2764 / PTK 0796 Compared to Other Agents</b>
Sept 27-30, 2006	ICAAC	F1-1974	Craig	<b>In Vivo Pharmacodynamics of MK-2764 / PTK 0796 Against Various Gram-positive and Gram-negative Bacteria in the Thighs of Neutropenic and Normal Mice</b>

Sept 27-30, 2006	ICAAC	F1-1972	DuBois	<b>In Vitro Activity of MK-2764 / PTK 0796 Against Legionella spp.</b>
Sept 27-30, 2006	ICAAC	F1-1973	Tessier	<b>Pharmacokinetic/Pharmacodynamic Profile of MK-2764 / PTK 0796 against S. pneumoniae in a Murine Pneumonia Model</b>
May 1-4, 2004	ECCMID	P926	Maccone	<b>Potent activity of BAY 73-7388, a Novel Aminomethylcycline, Against Susceptible and Resistant Gram-positive and Gram-negative Organisms</b>
May 1-4, 2004	ECCMID	P928	Endermann	<b>BAY 73-7388 is Highly Efficacious in Animal Models of Intraabdominal Infections Caused by a Range of Aerobic and Anaerobic Organisms, Including VRE</b>
May 1-4, 2004	ECCMID	P930	Broetz-Oesterhelt	<b>Superior Efficacy of BAY 73-7388, a Novel Aminomethylcycline, Compared with Linezolid and Vancomycin in Murine Sepsis Caused by Susceptible or Multiresistant Staphylococci</b>
May 1-4, 2004	ECCMID	P925	Bhatia	<b>Activity of BAY 73-7388, a Novel Aminomethylcycline, and Other Novel Antibiotic Classes Against Resistant Bacteria In Vitro</b>
May 1-4, 2004	ECCMID	P927	McKenney	<b>BAY 73-7388, a Novel Aminomethylcycline, Exhibits Potent Efficacy in Pulmonary Murine Models of Infection</b>
May 1-4, 2004	ECCMID	P929	Ladel	<b>BAY 73-7388 Demonstrates Greater Activity than Linezolid in a Range of Murine Models of Skin and Soft Tissue Infection</b>
May 1-4, 2004	ECCMID	P931	Endermann	<b>BAY 73-7388, a Novel Aminomethylcycline, is Highly Active In Vivo in a Murine Model of Pneumococcal Pneumonia</b>
Sept 14-17, 2003	ICAAC	F-751	Weir	<b>The Mechanism of Action of PTK 0796 (BAY 73-6944)</b>
Sept 14-17, 2003	ICAAC	F-752	Weir	<b>The Activity of PTK 0796 (BAY 73-6944) Against Tetracycline Resistance</b>
Sept 14-17, 2003	ICAAC	F-753	Traczewski	<b>PTK 0796 (BAY 73-6944): In Vitro Potency and Spectrum of Activity Compared to Ten Other Antimicrobial Compounds</b>
Sept 14-17, 2003	ICAAC	F-754	Maccone	<b>In Vitro Activity of PTK 0796 (BAY 73-6944) Against Gram-Positive and Gram-Negative Organisms</b>
Sept 14-17, 2003	ICAAC	F-755	Bhatia	<b>PTK 0796 (BAY 73-6944) and other Novel Tetracycline Derivatives Exhibiting Potent in vitro and in vivo Activities Against Antibiotic Resistant Gram-Positive Bacteria</b>
Sept 14-17, 2003	ICAAC	F-756	Traczewski	<b>PTK 0796 (BAY 73-6944): Effects of Environmental Variation on MICs and Confirmation of Disk Mass</b>

Sept 14-17, 2003	ICAAC	F-757	McKenney	<b>Evaluation of PTK 0796 (BAY 73-6944) in Experimental Models of Infections Caused by Gram-Positive and Gram-Negative Pathogens</b>
Sept 14-17, 2003	ICAAC	F-758	McKenney	<b>The Efficacy of PTK 0796 (BAY 73-6944) in Murine Models of Streptococcus pneumoniae Infections</b>
Sept 14-17, 2003	ICAAC	F-759	Cannon	<b>Pharmacokinetics of PTK 0796 (BAY 73-6944) in Mouse, Rat and Cynomolgus Monkey</b>
Sept 14-17, 2003	ICAAC	F-760	Chaturvedi	<b>In Vitro Assessment of Plasma Protein Binding and Metabolic Stability of PTK 0796 (BAY 73-6944)</b>